Navigation Links
Signum Biosciences Names Braham Shroot as Chief Executive Officer

PRINCETON, N.J., Aug. 5 /PRNewswire/ -- Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer.  Dr. Shroot replaces Dr. Gregory Stock who will continue to remain active with the Company as a member of the board.

"Braham Shroot brings to Signum an outstanding track record of success in growing value at both start-up and major pharmaceutical companies including Barrier Therapeutics, DFB Bioscience, and Galderma," said Maxwell Stock, President of Signum Biosciences. "We welcome him to the Signum team and look forward to seeing the company progress under his leadership."  

"This is a very exciting time for Signum, with the commercialization of the company's first skin-care compound, Arazine™,  by its partner, Rohto Pharmaceutical in Japan," said Dr. Shroot. "I am equally enthusiastic about Signum's innovative pipeline which holds significant potential to help patients with difficult-to-treat chronic inflammatory and age related pathologies."

Braham Shroot Biography

Braham Shroot is the former CSO of Barrier Therapeutics, Inc., a public dermatology-focused pharmaceutical company, which was acquired by Stiefel Laboratories Inc., in August 2008.  Prior to Barrier, Dr. Shroot was CSO and Vice President of R&D for DFB Pharmaceuticals, Inc., a fully integrated private specialty pharmaceutical company with a focus on skin, wound care, and surgical markets. Before DFB, Dr. Shroot was at L'Oreal where he was Group Leader and eventually Vice General Manager of the newly created Galderma entity which he helped to establish.  Dr. Shroot earned his B.Sc. in Chemistry and Ph.D. in Organic Chemistry at Glasgow University, Scotland, UK.  He is also a board member of the Wound Healing Society, and associate Editor of the Journal of Investigative Dermatology.

About Signum Biosciences

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for inflammatory and neurodegenerative diseases. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

For more information please visit the Signum website:

SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. 30, ... BCLI ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd., has been awarded an additional grant of ... the Chief Scientist (OCS). This grant, the second this year, ... activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):